News Release
Journal Article Cites HemoVoid™in Proteomic Study of Schizophrenia
MONMOUTHJUNCTION, NJ, May20, 2022-- Biotech Support Group reports on a research article describing thesimplicity and efficiency of their hemoglobin depletion technologyfor enriching blood proteins, in order to profile the proteome ofschizophrenia patients relative to normal controls.
Thecitation is:
Wang,Jijun, et al. "TheD2R-DISC1 protein complex and associated proteins are altered inschizophrenia and normalized with antipsychotic treatment." Journalof Psychiatry and Neuroscience 47.2(2022): E134-E147.
Thedopamine D2 receptor (D2R) is the main target of antipsychoticmedications, but its mechanism remains unclear, though elevatedlevels of the D2R-Disrupted-in-schizophrenia 1 (DISC1) complex inpostmortem brain tissue of patients with schizophrenia have beenfound.The study used coimmunoprecipitationto measure D2R-DISC1 complex levels in peripheral blood samples frompatients with schizophrenia and unaffected controls, along withlabel-free proteomic analysis.The article states “Blood…samples underwent total protein extraction with the HemoglobinDepletion and Protein Enrichment kit (Biotech Support Group)”, ourproduct called HemoVoid™. The report identified proteins andpathways that were associated with antipsychotic treatment inschizophrenia, and that may also be novel targets for schizophreniatreatment.
“Throughmore efficient methods to measure the blood proteome – red cells,white cells, platelets and plasma, our products now contribute tounderstanding how these compartments cross-communicate. Thoseconnections all play a role in normal homeostasis and in disease.This article illustrates how the blood proteome can be analyzed byLC-MS, in order to better understand schizophrenia.”, states SwapanRoy, Ph.D., President and Founder of Biotech Support Group.
Formore information on HemoVoid™, visit:
http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm
Formore information of all of our Hemoglobin removal products, visit:
https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for expanding proteomic analysis.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area. For this market, keyproducts include: AlbuVoid™ and AlbuSorb™ PLUS foralbumin & IgG depletion, Cleanascite™for lipid adsorption, and HemogloBind™ and HemoVoid™ forhemoglobin removal. From these innovations, the company has acquiredknowledgebase and biomarker intellectual property assets that supportdiscoveries of protein markers from blood, with special emphasis onearly detection and personalized medical decisions for cancerpatients. For more information, go tohttp://www.biotechsupportgroup.com
Forbusiness development contact: Matthew Kuruc
732-274-2866[email protected]